β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.
Although deregulation of the Wnt signalling pathway has been implicated in urothelial cell carcinoma (UCC), the functional significance is unknown. To test its importance, we have targeted expression of an activated form of β-catenin to the urothelium of transgenic mice using Cre-Lox technology (UroIICRE(+) β-catenin(exon3/+)). Expression of this activated form of β-catenin led to the formation of localized hyperproliferative lesions by 3 months, which did not progress to malignancy. These lesions were characterized by a marked increase of the phosphatase and tensin homologue (PTEN) tumour suppressor protein. This appears to be a direct consequence of activating Wnt signalling in the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult bladder led rapidly to coincident β-catenin and PTEN expression. This PTEN expression blocked proliferation. Next, we combined PTEN deficiency with β-catenin activation and found that this caused papillary UCC. These tumours had increased pAKT signalling and were dependent on mammalian target of rapamycin (mTOR). Importantly, in human UCC, there was a significant correlation between high levels of β-catenin and pAKT (and low levels of PTEN). Taken together these data show that deregulated Wnt signalling has a critical role in promoting UCC, and suggests that human UCC that have high levels of Wnt and PI3 kinase signalling may be responsive to mTOR inhibition.
Ahmad
I
I
The Beatson Institute for Cancer Research, Glasgow, Scotland, UK.
Morton
J P
JP
Singh
L B
LB
Radulescu
S M
SM
Ridgway
R A
RA
Patel
S
S
Woodgett
J
J
Winton
D J
DJ
Taketo
M M
MM
Wu
X-R
XR
Leung
H Y
HY
Sansom
O J
OJ
D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics; D000818:Animals; D002291:Carcinoma, Papillary / Q000378:metabolism*; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced; D008297:Male; D051379:Mice; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000032:analysis / Q000378:metabolism; D017384:Sequence Deletion; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D001743:Urinary Bladder / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*; D019459:Urothelium / Q000378:metabolism; D051153:Wnt Proteins / Q000378:metabolism; D051176:beta Catenin / Q000378:metabolism*
D025601:Adenomatous Polyposis Coli Protein; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D051153:Wnt Proteins; D051176:beta Catenin; C546842:MTOR protein, human; C546843:mTOR protein, mouse; C487757:Pten protein, mouse
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16
16609023
Int J Oncol. 2002 May;20(5):905-11
11956582
Cell. 2000 Oct 13;103(2):311-20
11057903
Cancer Res. 1999 Jul 15;59(14):3512-7
10416618
J Urol. 2002 Nov;168(5):2220-6
12394763
Nature. 1999 Apr 1;398(6726):422-6
10201372
Science. 1997 Oct 3;278(5335):120-3
9311916
Cancer Res. 2009 Dec 15;69(24):9413-21
19951992
Nat Genet. 2008 Dec;40(12):1436-44
19011632
J Clin Invest. 2007 Feb;117(2):314-25
17256055
Cancer Res. 1996 Sep 15;56(18):4154-8
8797585
Cancer Res. 2001 Oct 1;61(19):7101-9
11585741
Cancer Res. 2005 Aug 15;65(16):7081-5
16103055
Clin Cancer Res. 2006 Apr 15;12(8):2613-21
16638874
J Biol Chem. 2009 Dec 18;284(51):35308-13
19850932
Nucleic Acids Res. 2004 Jul 01;32(11):e92
15247325
Nat Rev Genet. 2004 Sep;5(9):691-701
15372092
Cancer Res. 2007 Jun 1;67(11):5371-9
17545618
Br J Cancer. 1999 May;80(5-6):904-8
10360673
Eur Urol. 2008 Oct;54(4):835-43
18166262
Am J Physiol Renal Physiol. 2005 Sep;289(3):F562-8
15840768
Histopathology. 2006 Jun;48(7):787-94
16722926
Int J Cancer. 1997 Jun 20;74(3):291-5
9221807
Clin Transl Oncol. 2007 Jan;9(1):5-12
17272224
Cell Metab. 2007 Oct;6(4):329-37
17908561
Nat Rev Cancer. 2005 Sep;5(9):713-25
16110317
Gastroenterology. 2004 May;126(5):1236-46
15131783
Cancer Res. 2006 Feb 15;66(4):1929-39
16488991
Cell. 2008 May 2;133(3):403-14
18455982
Cancer Biol Ther. 2004 Jan;3(1):36-41
14739782
Science. 1993 Dec 10;262(5140):1731-4
8259518
Clin Cancer Res. 2006 Jan 15;12(2):383-91
16428476
Eur Urol. 2006 May;49(5):839-45; discussion 845
16426728
Genesis. 2000 Nov-Dec;28(3-4):147-55
11105057
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Mol Cell Biol. 2008 Oct;28(20):6314-28
18694957
Eur J Cancer. 2000 Feb;36(3):357-62
10708937
Pathol Int. 2000 Dec;50(12):945-52
11123760
EMBO J. 2005 Apr 20;24(8):1571-83
15791206
Minerva Urol Nefrol. 2008 Dec;60(4):205-16
18923358
Genesis. 2002 Feb;32(2):148-9
11857804
Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65
18815930
Genes Dev. 2000 Aug 1;14(15):1837-51
10921899
EMBO J. 1999 Nov 1;18(21):5931-42
10545105
Cancer Res. 2006 Sep 1;66(17):8389-96
16951148
Int J Cancer. 2009 Jan 1;124(1):103-8
18844223
Oncogene. 2001 Apr 12;20(16):1973-80
11360181
Genes Dev. 2009 Mar 15;23(6):675-80
19261747
Anticancer Res. 2000 Nov-Dec;20(6B):4571-8
11205306
Int J Cancer. 2006 Oct 1;119(7):1513-8
16557569
J Urol. 1996 Apr;155(4):1444-7
8632608
Cancer Res. 1997 Dec 1;57(23):5221-5
9393738
Science. 1998 Sep 4;281(5382):1509-12
9727977
Science. 1991 Aug 9;253(5020):661-5
1651562
Lancet. 1992 Sep 12;340(8820):626-30
1355210